< Back to situations

[ORGANIZATION]

Takeda Pharmaceuticals

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [JP] [CN]

FDA, Japan, and China approve Orzeyful for narcolepsy

4 clusters · 9 sources · last updated

Latest: Orzeyful receives global approvals for narcolepsy type 1 treatment

The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton), the first oral orexin-2 receptor agonist for adults with narcolepsy type 1. Unlike previous treatments that manage symptoms, Orzeyful ta

[QUIET] [HEALTH] [US]

FDA approval of Lisraya for dermatomyositis

2 clusters · 15 sources · last updated

Latest: FDA approves new treatments for dermatomyositis and polycythemia vera

The U.S. Food and Drug Administration (FDA) has approved Lisraya (brepocitinib), developed by Priovant Therapeutics, as the first targeted oral therapy specifically for adults with dermatomyositis. This rare autoimmune d